The estimated Net Worth of Management Vii Llctechnolog... is at least $1.88 million dollars as of 7 March 2018. Management Llctechnolog owns over 22,682 units of Soleno Therapeutics Inc stock worth over $1,788,861 and over the last 7 years Management sold SLNO stock worth over $92,089.
Management has made over 2 trades of the Soleno Therapeutics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Management sold 22,682 units of SLNO stock worth $46,044 on 7 March 2018.
The largest trade Management's ever made was selling 22,682 units of Soleno Therapeutics Inc stock on 7 March 2018 worth over $46,044. On average, Management trades about 22,682 units every 0 days since 2018. As of 7 March 2018 Management still owns at least 36,823 units of Soleno Therapeutics Inc stock.
You can see the complete history of Management Llctechnolog stock trades at the bottom of the page.
Management's mailing address filed with the SEC is 100 Shoreline Hwy, Bldg. B, #100, Mill Valley, CA 94941, United States.
Over the last 9 years, insiders at Soleno Therapeutics Inc have traded over $134,327,999 worth of Soleno Therapeutics Inc stock and bought 56,592,152 units worth $70,324,676 . The most active insiders traders include Advisors Llcperceptive Life..., Jack W Schuler et Andrew Sinclair. On average, Soleno Therapeutics Inc executives and independent directors trade stock every 29 days with the average trade being worth of $36,911,570. The most recent stock trade was executed by Kristen Yen on 28 August 2024, trading 10,705 units of SLNO stock currently worth $507,738.
soleno therapeutics, inc. is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. the company is currently advancing its lead candidate, dccr, a once-daily oral tablet for the treatment of pws, into a phase iii clinical development program in early 2018.
Soleno Therapeutics Inc executives and other stock owners filed with the SEC include: